Table 1 Patient and treatment characteristics
Deidentified number | Gender | Race | Ethnicity | Age at diagnosis | B-SX at DX | Initial stage | IPI | Bulky > 10 cm | 1st line of therapy | At least one relapse | 2nd line of therapy | 3rd line of therapy | 4th line of therapy | FU in months | Status at last FU |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PML01 | Male | white | not Hispanic | 46 | No | II | 1 | Yes | 6xDA-R-EPOCH | No | 18 | Alive | |||
PML02 | Female | Asian | not Hispanic | 30 | No | II | 1 | Yes | 6xDA-R-EPOCH | No | 32 | Alive | |||
PML03 | Male | white | Hispanic | 36 | No | IV | 2 | No | 6xDA-R-EPOCH | No | 21 | Alive | |||
PML04 | Male | white | not Hispanic | 54 | No | IV | 2 | Yes | 6xDA-R-EPOCH | Yes | 3xR-ICE, ASCT and XRT | 65 | Alive | ||
PML05 | Male | American Indian | not Hispanic | 38 | No | I | 1 | Yes | 6xDA-R-EPOCH | No | 26 | Alive | |||
PML06 | Female | Hawaiian/Pacific Islander | Hispanic | 29 | Yes | II | 1 | Yes | 6xDA-R-EPOCH | Yes | 1 × R-DHAP | 1xR-ICE, Liso-cel | 29 | Alive | |
PML07 | Male | white | NA | 30 | Yes | III | 1 | Yes | 1xABVD + 6xDA-R-EPOCH | Yes | 3xR-DHAP, then ASCT | Selinexor and Rituximab | Rituximab + fractionated Cyclophosphamide | 15 | Dead |
PML08 | Female | white | not Hispanic | 24 | Yes | IV | 2 | No | 6xDA-R-EPOCH | No | 38 | Alive | |||
PML09 | Female | white | not Hispanic | 50 | Yes | IV | 3 | Yes | 6xDA-R-EPOCH | Yes | 1xR-DHAP | Tisa-cel | 7xPembrolizumab + XRT | 31 | Alive |
PML10 | Male | white | not Hispanic | 22 | No | II | 0 | No | 4xDA-R-EPOCH | No | 35 | Alive | |||
PML11 | Male | white | not Hispanic | 38 | Yes | III | 1 | No | 1xR-CHOP + Len, + 5xDA-R-EPOCH | No | 37 | Alive | |||
PML12 | Female | white | not Hispanic | 28 | No | IV | 1 | No | 5xDA-R-EPOCH | Yes | Axi-cel | 8xPembrolizumab, ASCT and XRT | 57 | Alive |